Join
Live feed
·
PRReleasevia Quantisnow
Deciphera Pharmaceuticals Inc. logo

Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT

ByQuantisnow·Wall Street's wire, on your screen.
DCPH· Deciphera Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DCPH (Deciphera Pharmaceuticals Inc.) and more on Quantisnow.